Cargando…
2556. A Phase 1, Open-Label, Single Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Epetraborole Tablets and the Impact of Alcohol Dehydrogenase (ADH) Genotype on the PK of Epetraborole and Metabolite M3 in Healthy Japanese Adult Subjects
BACKGROUND: Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria, is under clinical development for treatment-refractory MAC lung disease. Nonclinical studies suggest that metabolism of EBO to metabolite M...
Autores principales: | Patel, Gina, Castañeda-Ruiz, Bibiana, Yoshihara, Tatsuya, Krause, Kevin M, O’Shea, Kevin, Kammerer, Linda, Maier, Gary, Long, Jennifer, Smith, Alex, Chanda, Sanjay, Moore, Stephanie, Eckburg, Paul B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677986/ http://dx.doi.org/10.1093/ofid/ofad500.2173 |
Ejemplares similares
-
2144. A Phase 1, Multicenter, Open-Label, Parallel-Group Study to Assess the Safety and Pharmacokinetics (PK) of Oral Epetraborole Tablets in Adult Subjects with Varying Degrees of Renal Function
por: Patel, Gina, et al.
Publicado: (2023) -
1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease
por: Eckburg, Paul B, et al.
Publicado: (2022) -
Epetraborole Is Active against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021) -
Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline
por: Sullivan, Jaryd R., et al.
Publicado: (2021) -
1716. In Vitro Drug-Drug Interaction Evaluation of Epetraborole, a Novel Bacterial Leucyl-tRNA Synthetase Inhibitor
por: Shafiee, Afshin, et al.
Publicado: (2022)